



## Announcement Summary

**Entity name**

CLARITY PHARMACEUTICALS LTD

**Date of this announcement**

Monday November 25, 2024

**The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
New class - code to be confirmed	Options expiring 20 November 2029 ex. price \$5.505	357,925	20/11/2024
New class - code to be confirmed	Options expiring 20 November 2029 ex. price \$8.7703	20,987	20/11/2024
New class - code to be confirmed	Options expiring 20 November 2029 ex. price \$5.005	668,741	20/11/2024
New class - code to be confirmed	Options expiring 20 November 2029 ex. price \$7.973	151,369	20/11/2024
New class - code to be confirmed	Options expiring 20 November 2029 ex. price \$5.505	51,240	20/11/2024
New class - code to be confirmed	Options expiring 20 November 2029 ex. price \$7.311	7,756	20/11/2024

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

CLARITY PHARMACEUTICALS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ACN

**Registration number**

143005341

**1.3 ASX issuer code**

CU6

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

25/11/2024



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

does not have an existing ASX security code ("new class")



## Part 3C - number and type of +securities the subject of this notification (new class)

**ASX +security code**

New class - code to be confirmed

**+Security description**

Options expiring 20 November 2029 ex. price \$5.505

**+Security type**

Options

**ISIN code****Date the +securities the subject of this notification were issued**

20/11/2024

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Alan Taylor	Alan Taylor	258,246
Colin Biggin	Colin Biggin	99,679

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)

## Options Details

**+Security currency**

AUD - Australian Dollar

**Exercise price**

AUD 5.50500000

**Expiry date**

20/11/2029

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

CU6 : ORDINARY FULLY PAID

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest as follows, subject to the option holder remaining employed by the company:

25% on 1 July 2025

25% on 1 July 2026

50% on 1 July 2027



## Issue details

**Number of +securities**

357,925

**ASX +security code**

New class - code to be confirmed

**+Security description**

Options expiring 20 November 2029 ex. price \$8.7703

**+Security type**

Options

**ISIN code****Date the +securities the subject of this notification were issued**

20/11/2024

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Michelle Parker	Michelle Parker	20,987

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**
[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)

## Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 8.77030000	20/11/2029

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

CU6 : ORDINARY FULLY PAID

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**
[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest as follows, subject to the option holder remaining employed by the company:  
 25% on 10 October 2025  
 25% on 10 October 2026  
 50% on 10 October 2027

## Issue details

**Number of +securities**

20,987

**ASX +security code**

New class - code to be confirmed

**+Security description**

Options expiring 20 November 2029 ex. price \$5.005

**+Security type**

Options

**ISIN code****Date the +securities the subject of this notification were issued**

20/11/2024

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Alan Taylor	Alan Taylor	482,502
Colin Biggin	Colin Biggin	186,239

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**
[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)

## Options Details

**+Security currency**

AUD - Australian Dollar

**Exercise price**

AUD 5.00500000

**Expiry date**

20/11/2029

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

CU6 : ORDINARY FULLY PAID

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest 30 June 2027, subject to the option holder remaining employed by the company at all times during the Performance Period .

## Issue details

**Number of +securities**

668,741

**ASX +security code**

New class - code to be confirmed

**+Security description**

Options expiring 20 November 2029 ex. price \$7.973

**+Security type**

Options

**ISIN code****Date the +securities the subject of this notification were issued**

20/11/2024

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Michelle Parker	Michelle Parker	151,369

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)

## Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 7.97300000	20/11/2029

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

CU6 : ORDINARY FULLY PAID

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest 30 June 2027, subject to the option holder remaining employed by the company at all times during the Performance Period .

## Issue details

**Number of +securities**

151,369

**ASX +security code**

New class - code to be confirmed

**+Security description**

Options expiring 20 November 2029 ex. price \$5.505

**+Security type**

Options

**ISIN code****Date the +securities the subject of this notification were issued**

20/11/2024

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Chris Roberts	Chris Roberts	17,080
Thomas Ramdahl	Thomas Ramdahl	17,080
Rosanne Robinson	Rosanne Robinson	17,080

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)





## Options Details

<b>+Security currency</b>	<b>Exercise price</b>	<b>Expiry date</b>
AUD - Australian Dollar	AUD 5.50500000	20/11/2029

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

CU6 : ORDINARY FULLY PAID

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest 1 July 2025.

## Issue details

**Number of +securities**

51,240

**ASX +security code**

New class - code to be confirmed

**+Security description**

Options expiring 20 November 2029 ex. price \$7.311

**+Security type**

Options

**ISIN code****Date the +securities the subject of this notification were issued**

20/11/2024

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

No

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)

## Options Details

<b>+Security currency</b>	<b>Exercise price</b>	<b>Expiry date</b>
AUD - Australian Dollar	AUD 7.31100000	20/11/2029



**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

CU6 : ORDINARY FULLY PAID

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

[www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf](http://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf)

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Options vest as follows, subject to the option holder remaining employed by the company:

25% on 20 November 2025

25% on 20 November 2026

50% on 20 November 2027

---

Issue details

**Number of +securities**

7,756

---





## Part 4 - +Securities on issue

**Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
CU6 : ORDINARY FULLY PAID	320,211,465

**4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
CU6AV : OPTION EXPIRING 01-JULY-2028 EX \$0.79	2,528,202
CU6AW : OPTION EXPIRING 01-JULY-2028 EX \$0.84	45,207
CU6AAF : OPTION EXPIRING 18-SEP-2029 EX \$8.276	9,421
CU6AAG : OPTION EXPIRING 01-OCT-2029 EX \$9.424	16,677
CU6AO : OPTION EXPIRING 26-MAY-2027 EX \$1.40	400,000
CU6AZ : OPTION EXPIRING 24-NOV-2028 EX \$0.721	1,001,946
CU6AY : OPTION EXPIRING 24-NOV-2028 EX \$0.793	1,692,023
CU6AX : OPTION EXPIRING 05-SEP-2028 EX \$1.11	83,131
CU6AP : OPTION EXPIRING 01-JUL-2027 EX \$0.508	2,315,381
CU6AT : OPTION EXPIRING 06-MAR-2028 EX \$0.97	60,000
CU6AQ : OPTION EXPIRING 12-SEP-2027 EX \$0.725	162,500
CU6AM : OPTION EXPIRING 18-DEC-2024 EX \$0.83	700,000
CU6AN : OPTION EXPIRING 10-MAY-2026 EX \$0.94	4,820,000
CU6AR : OPTION EXPIRING 24-NOV-2027 EX \$0.508	1,921,081
CU6AS : OPTION EXPIRING 14-NOV-2027 EX \$1.06	161,771



CU6AAC : OPTION EXPIRING 01-JUL-2029 EX \$5.505	1,361,848
CU6AAD : OPTION EXPIRING 01-AUG-2029 EX \$6.952	10,000
CU6AAE : OPTION EXPIRING 08-JUL-2029 EX \$5.643	8,000
CU6AU : OPTION EXPIRING 01-MAY-2028 EX \$0.845	72,235
New class - code to be confirmed : Options expiring 20 November 2029 ex. price \$5.505	357,925
New class - code to be confirmed : Options expiring 20 November 2029 ex. price \$8.7703	20,987
New class - code to be confirmed : Options expiring 20 November 2029 ex. price \$5.005	668,741
New class - code to be confirmed : Options expiring 20 November 2029 ex. price \$7.973	151,369
New class - code to be confirmed : Options expiring 20 November 2029 ex. price \$5.505	51,240
New class - code to be confirmed : Options expiring 20 November 2029 ex. price \$7.311	7,756



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

Yes

**5.1a Select the number of the applicable exception in Listing Rule 7.2**

13